When biosimilars were first introduced in the U.S. in 2015, it was expected that they would deliver equally effective treatment to patients as their reference products, at a reduced cost for cancer programs and patients. However, it can be difficult to explain to patients that biosimilars may be their best—and most cost-effective—option.

On this episode of CANCER BUZZ, Miami Cancer Institute shares their unique approach to patient understanding: a biosimilars education course that explains what biosimilars are, how they are used, the testing process they go through, and how their use can affect insurance approvals and out-of-pocket expenses. Guests:

• Ana Chayeb, RN, Nurse Navigator, Miami Cancer Institute
• Peggy Bullard, RN, Rapid Treatment Nurse, Miami Cancer Institute
• Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE, Assistant Vice President - System Oncology Pharmacy Services, Non-Oncology Infusion Center Pharmacy Services, Miami Cancer Institute

Related Content:

• ACCC Biosimilars Education Center
• They’re Here—Cancer Biosimilars Enter U.S. Market
• The Year of the Biosimilar
• Media Issue Brief: Biosimilars, American Society of Clinical Oncology
• "When Will Biosimilars Start Making a Serious Difference in Oncology?,” Managed Healthcare Executive

The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.